Literature DB >> 11059870

Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels.

B Kronenberger1, B Rüster, J H Lee, C Sarrazin, W K Roth, G Herrmann, S Zeuzem.   

Abstract

BACKGROUND/AIMS: Some patients chronically infected with the hepatitis C virus (HCV) have persistently normal alanine aminotransferase (ALT) levels while progressive liver damage is observed histologically. In the present study, we compared the rate of proliferation, apoptosis, and necrosis in liver biopsy specimens of patients with persistently normal or elevated ALT levels.
METHODS: Fourteen patients with persistently normal and 14 age- and sex-matched patients with elevated ALT levels were enrolled. Proliferation was detected using anti-Ki 67 in 10-microm liver biopsy specimens of the patients. Apoptosis was measured by TUNEL-assay and by monoclonal anti-M30 directed against caspase-cleaved cytokeratin 18 filaments.
RESULTS: The mean number of anti-Ki 67 positive hepatocytes was lower in patients with persistently normal aminotransferases (3.1 +/- 2.8/10(3) vs 10.8 +/- 8.8/10(3) hepatocytes, p<0.0011) and was correlated with serum ALT (r=0.86, p<0.01) and aspartate aminotransferase levels (r=0.83, p<0.01). The rate of apoptosis detected by TUNEL assay was low and not different between patients with persistently normal and elevated aminotransferases. Staining with anti-M30 revealed a granular staining pattern and showed a trend towards higher cell death rates in patients with elevated aminotransferase levels (apoptotic hepatocytes with >75% staining: 3.97 +/- 6.24/10(3) hepatocytes vs 13.65 +/- 19.41/10(3) hepatocytes; p=0.08).
CONCLUSIONS: Patients with chronic hepatitis C and normal aminotransferases have significantly lower hepatocyte proliferation rates and show a trend towards lower apoptosis rates compared with patients with elevated aminotransferases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11059870     DOI: 10.1034/j.1600-0641.2000.033004640.x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis.

Authors:  Brian Webster; Silke Wissing; Eva Herker; Melanie Ott; Warner C Greene
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

2.  Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.

Authors:  Frederik Graw; Ashwin Balagopal; Abraham J Kandathil; Stuart C Ray; David L Thomas; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-11-13       Impact factor: 4.475

3.  Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

Authors:  Valeria Cento; Thi Huyen Tram Nguyen; Domenico Di Carlo; Elisa Biliotti; Laura Gianserra; Ilaria Lenci; Daniele Di Paolo; Vincenza Calvaruso; Elisabetta Teti; Maddalena Cerrone; Dante Romagnoli; Michela Melis; Elena Danieli; Barbara Menzaghi; Ennio Polilli; Massimo Siciliano; Laura Ambra Nicolini; Antonio Di Biagio; Carlo Federico Magni; Matteo Bolis; Francesco Paolo Antonucci; Velia Chiara Di Maio; Roberta Alfieri; Loredana Sarmati; Paolo Casalino; Sergio Bernardini; Valeria Micheli; Giuliano Rizzardini; Giustino Parruti; Tiziana Quirino; Massimo Puoti; Sergio Babudieri; Antonella D'Arminio Monforte; Massimo Andreoni; Antonio Craxì; Mario Angelico; Caterina Pasquazzi; Gloria Taliani; Jeremie Guedj; Carlo Federico Perno; Francesca Ceccherini-Silberstein
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

Review 4.  Hepatitis C virus-induced mitochondrial dysfunctions.

Authors:  Charlène Brault; Pierre L Levy; Birke Bartosch
Journal:  Viruses       Date:  2013-03-21       Impact factor: 5.048

5.  SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases.

Authors:  Tai-Nin Chau; Kam-Cheong Lee; Hung Yao; Tak-Yin Tsang; Tat-Chong Chow; Yiu-Cheong Yeung; Kin-Wing Choi; Yuk-Keung Tso; Terence Lau; Sik-To Lai; Ching-Lung Lai
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.